KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Operations: 2009-2024

Historic Cash from Operations for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Dec 2024 value amounting to -$8.3 million.

  • Alnylam Pharmaceuticals' Cash from Operations rose 643.84% to $325.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.9 million, marking a year-over-year increase of 370.10%. This contributed to the annual value of -$8.3 million for FY2024, which is 107.98% down from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Cash from Operations of -$8.3 million as of FY2024, which was down 107.98% from $104.2 million recorded in FY2023.
  • Alnylam Pharmaceuticals' Cash from Operations' 5-year high stood at $104.2 million during FY2023, with a 5-year trough of -$641.7 million in FY2021.
  • Its 3-year average for Cash from Operations is -$148.5 million, with a median of -$8.3 million in 2024.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Cash from Operations slumped by 120.87% in 2020 and then spiked by 119.24% in 2023.
  • Alnylam Pharmaceuticals' Cash from Operations (Yearly) stood at -$615.0 million in 2020, then decreased by 4.35% to -$641.7 million in 2021, then increased by 15.65% to -$541.3 million in 2022, then surged by 119.24% to $104.2 million in 2023, then tumbled by 107.98% to -$8.3 million in 2024.